BNP Paribas Exane Upgrades Cooper Companies (NASDAQ:COO) to "Outperform"

Cooper Companies (NASDAQ:COO - Get Free Report) was upgraded by BNP Paribas Exane from a "neutral" rating to an "outperform" rating in a report issued on Tuesday, Marketbeat reports. The brokerage currently has a $92.00 price objective on the medical device company's stock. BNP Paribas Exane's target price would suggest a potential upside of 29.00% from the stock's previous close.

A number of other research firms have also weighed in on COO. Needham & Company LLC raised Cooper Companies from a "hold" rating to a "buy" rating and set a $94.00 target price on the stock in a report on Tuesday, June 17th. Wall Street Zen downgraded shares of Cooper Companies from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. UBS Group upgraded shares of Cooper Companies to a "buy" rating in a research note on Tuesday, June 17th. Loop Capital set a $100.00 price target on shares of Cooper Companies in a research note on Tuesday, June 17th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $76.00 target price (down from $110.00) on shares of Cooper Companies in a report on Friday, May 30th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $96.73.

Cooper Companies Trading Down 1.8%

NASDAQ COO opened at $71.32 on Tuesday. The stock has a market capitalization of $14.26 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 1.77 and a beta of 0.99. Cooper Companies has a 52 week low of $65.00 and a 52 week high of $112.38. The stock's 50 day moving average price is $74.03 and its two-hundred day moving average price is $81.92. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.23 and a current ratio of 2.10.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings results on Thursday, May 29th. The medical device company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.03. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $995.12 million. Cooper Companies had a return on equity of 9.60% and a net margin of 10.39%. The business's quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.85 EPS. As a group, analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in COO. Zions Bancorporation National Association UT bought a new position in Cooper Companies in the 1st quarter valued at approximately $33,000. City Holding Co. acquired a new stake in Cooper Companies in the 1st quarter valued at $34,000. New Age Alpha Advisors LLC bought a new stake in shares of Cooper Companies during the 4th quarter worth $38,000. GKV Capital Management Co. Inc. purchased a new stake in Cooper Companies in the 1st quarter worth about $40,000. Finally, Covestor Ltd increased its holdings in Cooper Companies by 35.5% in the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company's stock worth $42,000 after acquiring an additional 120 shares during the last quarter. Institutional investors own 24.39% of the company's stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.